Table 3:
Clinicopathologic characteristics of MSK immunotherapy cohort.
| N=203 | |
|---|---|
| Age, mean (SD) | 62 (13) |
| Male, n (%) | 151 (74·0) |
| BMI, mean (SD) | 26·9 (6·3) |
| BMI category, n (%) | |
| Normal | 63 (31·0) |
| Overweight | 74 (36·5) |
| Obese | 66 (32·5) |
| IMDC risk group, n (%) | |
| Favorable | 35 (17·9) |
| Intermediate | 128 (65·3) |
| Poor | 33 (16·8) |
| Unknown | 7 |
| IO Treatment Line, n (%) | |
| First line | 48 (23·6) |
| ≥Second line | 155 (76·4) |
IO=immunotherapy. BMI=body mass index. SD=standard deviation.